Table 2 Uni- and multivariate analyses of clinicopathological factors for overall and relapse-free survival

Overall survival

Age, ≥ 70 vs. < 70

1.032

0.489–2.179

0.932

Gender, male vs. female

0.584

0.237–1.434

0.170

CEA, ≥ 5 vs. < 5

0.845

0.382–1.868

0.687

CA19-9, ≥ 37 vs. < 37

1.952

0.930–4.097

0.075

Complications, yes vs. no

1.619

0.564–4.646

0.280

Adjuvant chemotherapy, no vs. yes

2.897

0.566–14.84

0.035*

2.029

0.698–5.893

0.194

Pathological T stage ^a, 3/4 vs. 1/2

2.469

1.174–5.191

0.017*

1.845

0.723–4.706

0.200

Pathological N stage ^a, 1 vs. 0

2.211

0.944–5.183

0.031*

1.243

0.466–3.318

0.664

Intratumoral FAP, high vs. low

3.303

1.523–7.162

0.013*

2.450

1.005–5.972

0.049*

Recurrence-free survival

Age, ≥ 70 vs. < 70

0.939

0.446–1.977

0.862

Gender, male vs. female

0.837

0.368–1.903

0.654

CEA, ≥ 5 vs. < 5

0.792

0.362–1.737

0.571

CA19-9, ≥ 37 vs. < 37

1.789

0.852–3.752

0.126

Complications, yes vs. no

1.095

0.433–2.768

0.842

Adjuvant chemotherapy, no vs. yes

3.139

1.228–8.026

0.001*

1.693

0.589–4.868

0.328

Pathological T stage ^a, 3/4 vs. 1/2

2.564

1.218–5.396

0.009*

1.208

0.390–3.831

0.730

Pathological N stage ^a, 1 vs. 0

2.664

0.947–7.499

0.009*

1.846

0.692–4.925

0.221

Intratumoral FAP, high vs. low

3.870

1.812–8.263

0.003*

2.591

1.034–6.493

0.042*